Autonomix Medical

Autonomix Medical Equity

The The Equity of Autonomix Medical (AMIX) as of Oct 20, 2026 is 5.90 M USD. In the previous year, The Equity was 8.10 M USD — a change of -27.21% (lower).

Equity

5.90 MUSD

YoY

-27.21%

Last updated:

In 2026, Autonomix Medical's equity was 5.90 M USD, a -27.21% increase from the 8.10 M USD equity in the previous year.

The Autonomix Medical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
1.96 M USD
Jan 1, 2023
644,000.00 USD
Jan 1, 2024
7.63 M USD
Jan 1, 2025
8.10 M USD
Jan 1, 2026
5.90 M USD
The Autonomix Medical Equity history
YEAREquityYoY
5.90 MUSD-27.21%
8.10 MUSD+6.17%
7.63 MUSD+1,084.47%
644,000.00USD-67.13%
1.96 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autonomix Medical Stock analysis

What does Autonomix Medical do? Autonomix Medical Inc develops medical devices focused on treating peripheral nervous system diseases. The company's technology platform features a catheter-based microchip sensing array capable of detecting peripheral neural signals with up to 1,000 times sensitivity. It is developing a dual-function technology that both detects malfunctioning neural signals and ablates nerves in a single procedure for pain management. The company targets conditions like pancreatic cancer and pancreatitis, which cause severe pain requiring effective solutions. Its Autonomix catheter uses a microchip to convert body analog signals into digital signals for direct transmission to a computer. The company's products include the Autonomix catheter and its underlying technology platform. These are designed for medical professionals treating conditions involving the peripheral nervous system. The primary segments served are patients suffering from pancreatic cancer, pancreatitis, and other peripheral nervous system disorders requiring pain management solutions. The technology platform has potential applications across multiple medical fields including cardiology, renal denervation, and chronic pain management. Autonomix Medical Inc's revenue model is based on developing and commercializing its medical device technology. The company is focused on creating solutions for specific medical conditions where current treatments are inadequate. Its dual-function technology represents a novel approach to pain management by combining detection and ablation capabilities in one procedure. The company's target market includes healthcare providers seeking advanced solutions for peripheral nervous system diseases and chronic pain conditions. Autonomix Medical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Autonomix Medical's Equity

Autonomix Medical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Autonomix Medical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Autonomix Medical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Autonomix Medical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Autonomix Medical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Autonomix Medical stock

The Equity of Autonomix Medical is 5.90 M USD in 2026.

The Equity of Autonomix Medical changed from 8.10 M USD to 5.90 M USD, representing a -27.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Autonomix Medical since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Autonomix Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Autonomix Medical

All Key Metrics — Autonomix Medical